Fintepla Approval Status
FDA Approved: No
Brand name: Fintepla
Generic name: fenfluramine
Company: Zogenix, Inc.
Treatment for: Dravet Syndrome
Fintepla ((ZX008, low-dose fenfluramine) is an amphetamine derivative in development for the treatment of seizures associated with Dravet syndrome.
Fenfluramine was originally developed as an appetite suppressant and sold under the brand name Pondimin until it was withdrawn from the U.S. market in 1997.
Development Status and FDA Approval Process for Fintepla
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.